Niven R. Narain, PhD, President and CEO of BPGbio asks how a better calibre of biobanks in life sciences can lead to more drugs making it to market. Artificial Intelligence (AI) has become a popular buzzword in the drug discovery and development lexicon but not all approaches to AI-driven drug discovery produce meaningful insights […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!